Careers

Coming in the New Year: SLAS Discovery and SLAS Technology

In 2017, SLAS’s two scientific journals will begin their 22nd year of publication with new names and taglines! The journal we’ve known as the Journal of Biomolecular Screening (JBS) will become SLAS DiscoveryTM (Advancing Life Sciences R&D); and the journal we’ve known as the Journal of Laboratory Automation (JALA) will become SLAS TechnologyTM (Translating Life Sciences Innovation).

By Richard M. Eglen, Ph.D.

Since the journals were founded in 1996, they have maintained relevant leadership positions by evolving in lock-step with the dynamic life sciences discovery and technology community. These name changes reflect this evolution and more accurately express today’s SLAS and its critical position at the vibrant nexus of life sciences research and technology.

The SLAS journals are high-value priorities of the Society. Together they do an outstanding job of pioneering the range of issues and priorities important to the success of our scientific community. The new names simply are more accurate reflections of what has been and is being published in them. They are fresh, crisp and clear, and they reinforce the relationship between the journals and the Society and their shared educational priorities.

SLAS Discovery will continue to focus on advancing life sciences R&D, publishing reports of how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. SLAS Technology will continue to focus on translating life sciences innovation, publishing ways in which scientists adapt advancements in technology for scientific exploration and experimentation.

SLAS Discovery and SLAS Technology will maintain their commitment to best practices and continuous quality improvement. Both journals will continue to demand rigorous peer review and be backed by the world-class education standards of SLAS. We are fortunate that our journals benefit from the hands-on leadership and involvement of practicing life sciences professionals – editorial board members, manuscript authors, manuscript reviewers; respected experts with first-hand knowledge and experience. More than 1,000 of them engage with our journals every year and will continue to do so. In addition, SAGE Publications will continue as our well established and highly regarded publishing partner.

While our journal names are changing, their trusted commitment to innovation is not changing. SLAS Discovery and SLAS Technology’s editorial rigor, integrity, aims and scope will remain solidly and dependably in place:

Advancing Life Sciences R&D

SLAS Discovery is a peer-reviewed journal focusing on drug discovery sciences with a strong record of scientific rigor and impact. SLAS Discovery publishes scientific reports that enable and improve target validation, evaluate current drug discovery technologies, provide novel research tools, and incorporate research approaches that enhance depth of knowledge and drug discovery success. SLAS Discovery is an official journal of SLAS (Society for Laboratory Automation and Screening).

Translating Life Sciences Innovation

SLAS Technology explores ways in which scientists adapt advancements in technology for scientific exploration and experimentation.

SLAS Technology is a rigorously peer-reviewed, multi-disciplinary journal devoted to the advancement of technology for conducting life sciences and biomedical R&D. It is an official journal of SLAS (Society for Laboratory Automation and Screening), and provides a unique international forum for the presentation of method-focused scientific reports.

SLAS Technology emphasizes scientific and technical advances that enable and improve life sciences research and development; drug-delivery; diagnostics; biomedical and molecular imaging; and personalized and precision medicine. This includes high-throughput and other laboratory automation technologies; micro/nanotechnologies; analytical, separation and quantitative techniques; synthetic chemistry and biology; informatics (data analysis, statistics, bio, genomic and chemoinformatics); and more.

The decision to update the names of the SLAS journals was made after more than two years of research and consideration by members of the SLAS Journals Strategic Planning Task Forces, SLAS Americas Council, SLAS Europe Council and SLAS Board of Directors. The results of a series of stakeholder surveys reinforced the perceptions and misperceptions that led to the recommended changes. Authors, editorial board members, readers and even advertisers agreed that the existing names were incongruent with what SLAS truly is and what’s published in our journals.

Whether you’re a reader, author, reviewer or editorial board member, you are a stakeholder whose needs, priorities and vision define the editorial essence and excellence of our journals. We look forward to your continued partnership in the ongoing success of SLAS Discovery and SLAS Technology.

SHARE THIS ARTICLE

SHARE THIS ARTICLE

LATEST ARTICLES

Could hijacking one of the body’s own systems be the key to finding new targets for hard-to-treat diseases? Dane Mohl, Ph.D., scientist at Amgen (Thousand Oaks, CA) believes it may be. With the advent of genomics, drug development has focused on using genetics to identify therapeutic targets, which has led to targets that aren’t necessarily easily drugged through traditional methods. “Letting genetics guide our choices for treating disease means we have to use whatever modalities are available,” Mohl says. “We have to be more creative and that means we need a larger tool box to get to those new targets.”

It seems like just yesterday that I assumed the SLAS presidency at SLAS2018, last February in San Diego, and now the year is almost up! It’s time for me to say farewell and hand over the reins to my successor, Alan E. Fletcher, Ph.D., of PerkinElmer Discovery and Analytical Solutions (Hopkinton, MA, USA). I’ve really enjoyed my three years on the SLAS Board of Directors and am honored to have been given the opportunity to serve as the Society’s 2018 president.

Take a little wonder and the desire to do good. Throw in meaningful research experience, honest commitment, science smarts and a whole lot of energy, and you've taken one step toward describing SLAS's Scientific Director Michael (Mike) Tarselli, Ph.D. The Boston (MA, USA) native started his position with the Society in September of 2018, and finds his new role yet another way to make life better for scientists, engineers and the world.

This website or its third party tools use cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies. Find out more about our Privacy & Cookie policy ( non-EU | EU/UK ) and how to withdraw consent to all or some of the cookies. You can change your cookie settings at any time.